Synvisc-One 48 mg/10 ml Intra-articular Injection Uses, Dosage, Side Effects and more

2.25 mL glass syringe containing one 2 mL (16 mg) dose of hylan G-F 20. The contents of the syringe are sterile and nonpyrogenic.Hylan G-F is an elastoviscous high molecular weight fluid containing hylan A and hylan B polymers produced from chicken combs. Hylans are derivatives of hyaluronan (sodium hyaluronate). Synvisc-One 48 mg/10 ml Intra-articular Injection is unique in that the hyaluronan is chemically crosslinked. Hyaluronan is a long-chain polymer containing repeating disaccharide units of Na-glucuronate-N-acetylglucosamine.Hylan G-F is a gel-like mixture that comes in a syringe containing 6 mL (1 ½ teaspoon) and is injected into your knee. It is made up of hylan A fluid, hylan B gel, and salt water. Hylan A and hylan B are made from a substance called hyaluronan (pronounced hy-al-u-ROE-nan), also known as sodium hyaluronate that comes from chicken combs. Hyaluronan is a natural substance found in the body and is present in very high amounts in joints. The body’s own hyaluronan acts like a lubricant and a shock absorber in the joint and is needed for the joint to work properly.Joints contain a fluid, called synovial fluid, which acts as a lubricant and shock absorber. Patients with osteoarthritis have synovial fluid that is thinner than normal, and, therefore, it is less effective as a lubricant and shock-absorber. Synvisc-One 48 mg/10 ml Intra-articular Injection is an elastic fluid that is made from a substance called hyaluronan, that is found in normal joint fluid. Hyaluronan is the key substance in joint fluid that provides the shock-absorbing quality to the fluid, and it is essential for the proper functioning of joints. When Synvisc-One 48 mg/10 ml Intra-articular Injection is injected into the knee of a patient with osteoarthritis, the drug helps to restore the shock-absorbing effect of the fluid within the knee. This can reduce pain, resulting in a more active lifestyle.

Synvisc-One 48 mg/10 ml Intra-articular Injection
Trade Name Synvisc-One 48 mg/10 ml Intra-articular Injection
Generic Hylan G-F 20
Weight 48 mg/10 ml
Type Intra-articular Injection
Therapeutic Class Drugs for Osteoarthritis
Manufacturer Sanofi Bangladesh Ltd. (Mfg. by: Genzyme Corporation)
Available Country Bangladesh
Last Updated: January 7, 2025 at 1:49 am

Uses

Hylan G-F is used for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.
Pediatrics: The safety and effectiveness of Hylan G-F have not been established in pediatric patients. Pediatric patients are defined as patients ≤ 21 years of age.

Dosage

Synvisc-One 48 mg/10 ml Intra-articular Injection is administered by intra-articular injection once a week (one week apart) for a total of three injections. Strict aseptic administration technique must be followed.

Side Effects

The most commonly reported adverse events associated with Synvisc-One 48 mg/10 ml Intra-articular Injection are the following: Pain in the injected knee, Swelling in the injected knee, Joint effusion

See simplified version Synvisc-One 48 mg/10 ml Intra-articular Injection also Synvisc-One 48 mg/10 ml Intra-articular Injection in bangla

Precaution

Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject Hylan G-F extra-articularly or into the synovial tissues and capsule. Local and systemic adverse events, generally in the area of the injection, have occurred following extra-articular injection of Hylan G-F. Intravascular injections of Hylan G-F may cause systemic adverse events.

Interaction

No information provided.

Pregnancy & Breastfeeding use

Pregnancy: The safety and effectiveness of Synvisc-One 48 mg/10 ml Intra-articular Injection have not been established in pregnant women.

Nursing mothers: It is not known if Synvisc-One 48 mg/10 ml Intra-articular Injection is excreted in human milk. The safety and effectiveness of Synvisc-One 48 mg/10 ml Intra-articular Injection have not been established in lactating women.

Contraindication

Do not administer to patients with known hypersensitivity (allergy) to hyaluronan (sodium hyaluronate) preparations. Do not inject Hylan G-F in the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site

Storage Condition

Do not use Synvisc-One 48 mg/10 ml Intra-articular Injection if the package has been opened or damaged. Store in original packaging (protected from light) at room temperature below 86°F (30°C). DO NOT FREEZE.

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share